The scrip opened at Rs. 520.00 and has touched a high and low of Rs. 525.80 and Rs. 517.15 respectively.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 435.10 on 21-Jun-2019.
Last one week high and low of the scrip stood at Rs. 532.00 and Rs. 508.00 respectively. The current market cap of the company is Rs. 9620.91 crore.
The promoters holding in the company stood at 72.97%, while Institutions and Non-Institutions held 14.97% and 12.06% respectively.
US Food & Drug Administration (USFDA) has completed inspection at Alembic Pharmaceuticals’ Bioequivalence facility located at Vadodara. The agency had conducted inspection from August 12, 2019 to August 15, 2019 and from August 12, 2019 to August 20, 2019 for Bioequivalence Bioanalytical and Bioequivalence Clinical. There were no 483s issued by USFDA at the end of the inspection.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
